Access Bio products

Self Test for SARS-CoV-2 Antigen Detection. The CareStart™ COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2. Fast and easy to self-test at anywhere. Easy to interpret the results using mobile application. Qualitatively detect the SARS-CoV-2 nucleocapsid protein. Use for nasal swab specimen. Fast results only in 10 minutes. Identify individual’s current infection status to COVID-19.

The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

The CareStart™ COVID-19 MDx RT-PCR is a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens (such as nasopharyngeal, oropharyngeal and nasal swabs, and nasopharyngeal wash/aspirate or nasal aspirate) and bronchoalveolar lavage from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

The CareStart™ EZ HIV 1/2 is an in vitro RDT for the qualitative detection of antibodies to HIV type-1 and/or type-2 in serum, plasma, capillary whole blood or venous whole blood. The device is a single-use intended for healthcare professional use as an aid to diagnosis only – not for screening blood donors.

Influenza is a highly contagious viral infection of the nose, throat, and lungs that occurs most often in the late fall, winter, and early spring. Since other viruses infecting respiratory track have similar symptoms, it is critical to properly diagnose influenza viral infection before any treatment. Flu A&B Plus differentiates influenza A and B diagnosis with boldly colored test lines.

Recommended by the WHO during the Malaria Policy Advisory Meeting. G6PD deficiency is an X-linked recessive genetic disorder, resulting in no or low G6PD activity. G6PD deficienct patients are vulnerable to the spontaneous destruction of red blood cells when exposed to high oxidative stress. High oxidative stress may result from consumption of primaquine (antimalarial), aspirin, Fava beans, and menthol. There is no cure for the condition but the G6PD deficiency can be manageable.

Method comparison. careSURE™ Analyzer 100 vs. a laboratory HPLC method (Tosoh G11) Using 48 venous blood samples.

A neonatal solution, the S1 Analyzer is capable of quantifying total G6PD, Hemoglobin, and Bilirubin levels. Early diagnosis for newborns are crucial to ensure healthy development. The S1 Analyzer’s handheld format, with Bluetooth and wifi technology, affords patient-side accuracy and convenience.

In conjuction with real time PCR, it can differentiate HPV-16, HPV-18, and other high-risk HPV genotype.

Test Type: Molecular Diagnostics. Package: 96 tests/box. Specimen: RNAs from serum, Urine. Specimen Volume: DNA extract 5 μL. Result Time: 90 min. Storage Condition: below -20°C. Shelf life: 12 months.